Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions

Fig. 1

Principles of MEK inhibition in NF1 associated lesions. Legend: a NF1 pathogenic variants induce overactivation of the MAPK signaling cascade. Specific MEK inhibition blocks phosphorylation of ERK and subsequent signal transduction to the transcription network of the nucleus. b Apart from Neurofibromatosis type 1, somatic pathogenic NF1 gene variants occur in non-NF1 associated tumors and can be targeted by MEK inhibitors. c MEK inhibition is associated with side effects which occur at different percentages

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us